- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
18 result(s) found for: Anchor test.
Displaying page 1 of 1.
EudraCT Number: 2004-001482-17 | Sponsor Protocol Number: F1D-MC-HGKQ(b) | Start Date*: 2004-10-15 |
Sponsor Name:Eli Lilly and Company | ||
Full Title: Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar I disorder. | ||
Medical condition: Manic or Mixed Episodes Associated with Bipolar I Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004407-39 | Sponsor Protocol Number: IB1001-203 | Start Date*: 2019-09-18 |
Sponsor Name:IntraBio Ltd. | ||
Full Title: Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A multinational, multicenter, open-label, rater-blinded Phase II study. | ||
Medical condition: To demonstrate that N-Acetyl-L-Leucine is effective in improving symptoms, functioning, and quality of life in patients with Ataxia-Telangiectasia (A-T) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004331-71 | Sponsor Protocol Number: IB1001-201 | Start Date*: 2019-05-08 | |||||||||||
Sponsor Name:IntraBio Ltd | |||||||||||||
Full Title: Effects of N-Acetyl-L-Leucine on Niemann-Pick type C Disease (NPC): A multinational, multi-center, open-label, rater-blinded Phase II study | |||||||||||||
Medical condition: Niemann-Pick Disease type C (NPC) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005375-16 | Sponsor Protocol Number: A-99-52120-162 | Start Date*: 2012-02-20 | |||||||||||
Sponsor Name:Institut Produits Synthèse (IPSEN) AB | |||||||||||||
Full Title: A PHASE III PROSPECTIVE, MULTI-CENTER, RANDOMISED, EVALUATOR-BLINDED STUDY TO COMPARE NEUROMUSCULAR JUNCTION (NMJ) TARGETED TECHNIQUE FOR DYSPORT INJECTIONS IN UPPER LIMB SPASTICITY POST STROKE OR ... | |||||||||||||
Medical condition: Upper limb spasticity post stroke or traumatic brain injury. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FI (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000723-40 | Sponsor Protocol Number: 331-201-00148 | Start Date*: 2024-06-13 |
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | ||
Full Title: Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder | ||
Medical condition: Irritability Associated With Autism Spectrum Disorder (ASD) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-004406-25 | Sponsor Protocol Number: IB1001-202 | Start Date*: 2019-05-09 | |||||||||||
Sponsor Name:IntraBio Ltd | |||||||||||||
Full Title: Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A multinational, multicenter, open-label, rater-blinded Phase II study. | |||||||||||||
Medical condition: GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000687-33 | Sponsor Protocol Number: HOPE | Start Date*: 2015-11-18 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: Randomized placebo-controlled trial to investigate clinical efficacy, anti-inflammatory properties and safety of prednisolone in hand osteoarthritis: a proof-of-concept study | ||
Medical condition: Hand osteoarthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000751-42 | Sponsor Protocol Number: D1441C00150 | Start Date*: 2006-04-07 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in ... | ||
Medical condition: SCHIZOPHRENIA or BIPOLAR I DISORDER | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000606-37 | Sponsor Protocol Number: MesenSistem-EB | Start Date*: 2017-11-16 |
Sponsor Name:Fundación para la Investigación Biomédica Hospital Universitario La Paz | ||
Full Title: Safety and preliminary efficacy study of infusing mesenchymal stem cells derived from bone marrow for treating Recessive Dystrophic Epidermolysis Bullosa. | ||
Medical condition: Recessive Dystrophic Epidermolysis Bullosa | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004074-25 | Sponsor Protocol Number: 01KG1204 | Start Date*: 2013-10-30 | |||||||||||
Sponsor Name:Ruhr-Universität Bochum | |||||||||||||
Full Title: Comparison of the efficacy and safety of two different starting dosages of prednisolone in early active rheumatoid arthritis: a randomized, placebo controlled trial | |||||||||||||
Medical condition: Early rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000716-30 | Sponsor Protocol Number: RGL-003-001 | Start Date*: 2020-09-10 | |||||||||||
Sponsor Name:Gedeon Richter Plc. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter, proof-of-concept study to evaluate a combined oral contraceptive (COC) containing 30 µg ethinylestradiol and 150 µg levonorgestrel plus ... | |||||||||||||
Medical condition: Hypoactive sexual desire disorder (HSDD) secondary to combined oral contraception use. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) PL (Completed) CZ (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000972-40 | Sponsor Protocol Number: IM101-774 | Start Date*: 2020-06-09 | |||||||||||
Sponsor Name:Universitätsklinikum Freiburg | |||||||||||||
Full Title: Safety and Efficacy of abatacept (s.c.) in patients with CTLA4 insufficiency or LRBA deficiency | |||||||||||||
Medical condition: Patients with a molecular confirmed diagnosis of CTLA4 (cytotoxic T-lymphocyte-associated Protein 4) (haplo)-insufficiency or LRBA (Lipopolysaccharide-Responsive and Beige-like An¬chor) deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000750-22 | Sponsor Protocol Number: D1441C00112 | Start Date*: 2006-04-06 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase IIIb Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Immediate-release T... | |||||||||||||
Medical condition: SCHIZOPHRENIA | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002120-24 | Sponsor Protocol Number: OP-104 | Start Date*: 2017-12-14 | |||||||||||
Sponsor Name:Oncopeptides AB | |||||||||||||
Full Title: An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination with either Bortezomib or Daratumumab in Patients with Relapsed or Relapsed-Refractory Multip... | |||||||||||||
Medical condition: Patients with Relapsed or Relapsed-Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000271-32 | Sponsor Protocol Number: W00090GE201 | Start Date*: 2018-11-11 | |||||||||||
Sponsor Name:Pierre Fabre Médicament | |||||||||||||
Full Title: Phase II, open-label, single arm, multicenter study of encorafenib, binimetinib plus cetuximab in subjects with previously untreated BRAF V600E -mutant Metastatic Colorectal Cancer | |||||||||||||
Medical condition: BRAF V600E -mutant Metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Ongoing) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002545-42 | Sponsor Protocol Number: INS-415 | Start Date*: 2021-02-08 | |||||||||||
Sponsor Name:Insmed Incorporated | |||||||||||||
Full Title: ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects with Newly Diagnosed Nontuberculous M... | |||||||||||||
Medical condition: Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) DE (Completed) HU (Completed) AT (Completed) NL (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004395-34 | Sponsor Protocol Number: C4221026 | Start Date*: 2022-04-25 | ||||||||||||||||||||||||||
Sponsor Name:Pfizer Inc. | ||||||||||||||||||||||||||||
Full Title: ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES | ||||||||||||||||||||||||||||
Medical condition: solid tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) BE (Trial now transitioned) SK (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) PT (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001689-41 | Sponsor Protocol Number: RR11/9858 | Start Date*: 2013-11-20 | ||||||||||||||||||||||||||
Sponsor Name:University of Leeds | ||||||||||||||||||||||||||||
Full Title: Pain Reduction with Oral Methotrexate in knee Osteoarthritis, a pragmatic phase III trial of Treatment Effectiveness | ||||||||||||||||||||||||||||
Medical condition: Knee osteoarthritis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
